JPH02291284A - Novel 13c-labeled amino acid and its fermentative or its enzymatic preparation - Google Patents
Novel 13c-labeled amino acid and its fermentative or its enzymatic preparationInfo
- Publication number
- JPH02291284A JPH02291284A JP2034067A JP3406790A JPH02291284A JP H02291284 A JPH02291284 A JP H02291284A JP 2034067 A JP2034067 A JP 2034067A JP 3406790 A JP3406790 A JP 3406790A JP H02291284 A JPH02291284 A JP H02291284A
- Authority
- JP
- Japan
- Prior art keywords
- labeled
- amino acid
- medium
- glucose
- leucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title abstract description 3
- 230000002255 enzymatic effect Effects 0.000 title description 2
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 63
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 31
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 29
- 238000000855 fermentation Methods 0.000 claims abstract description 18
- 230000004151 fermentation Effects 0.000 claims abstract description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 9
- 238000006911 enzymatic reaction Methods 0.000 claims abstract description 7
- 150000001721 carbon Chemical group 0.000 claims description 27
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 5
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 84
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 50
- 239000002609 medium Substances 0.000 description 44
- 229940024606 amino acid Drugs 0.000 description 39
- 235000001014 amino acid Nutrition 0.000 description 39
- 229960003136 leucine Drugs 0.000 description 39
- 235000001727 glucose Nutrition 0.000 description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 31
- 239000008103 glucose Substances 0.000 description 31
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 23
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 239000004395 L-leucine Substances 0.000 description 18
- 235000019454 L-leucine Nutrition 0.000 description 18
- 108010073771 Soybean Proteins Proteins 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 230000001580 bacterial effect Effects 0.000 description 17
- 229960004295 valine Drugs 0.000 description 17
- 239000012141 concentrate Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
- 229960000310 isoleucine Drugs 0.000 description 12
- WQZGKKKJIJFFOK-UKLRSMCWSA-N dextrose-2-13c Chemical compound OC[C@H]1OC(O)[13C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-UKLRSMCWSA-N 0.000 description 11
- 235000019710 soybean protein Nutrition 0.000 description 11
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 9
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000003531 protein hydrolysate Substances 0.000 description 9
- 238000011218 seed culture Methods 0.000 description 9
- 229960000344 thiamine hydrochloride Drugs 0.000 description 9
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 9
- 239000011747 thiamine hydrochloride Substances 0.000 description 9
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 9
- 239000004474 valine Substances 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 229940001941 soy protein Drugs 0.000 description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 238000005273 aeration Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000003456 ion exchange resin Substances 0.000 description 6
- 229920003303 ion-exchange polymer Polymers 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- -1 tributophane Chemical compound 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 239000000052 vinegar Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000007836 KH2PO4 Substances 0.000 description 4
- 150000008544 L-leucines Chemical class 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 4
- 235000021419 vinegar Nutrition 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 229960001596 famotidine Drugs 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 229960004452 methionine Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000008521 threonine Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 239000004470 DL Methionine Substances 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000002304 glucoses Chemical class 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 238000000358 protein NMR Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- GHSJKUNUIHUPDF-BYPYZUCNSA-N L-thialysine Chemical compound NCCSC[C@H](N)C(O)=O GHSJKUNUIHUPDF-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 150000008554 L-valines Chemical class 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- VJHCJDRQFCCTHL-BTVCFUMJSA-N acetic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O VJHCJDRQFCCTHL-BTVCFUMJSA-N 0.000 description 1
- YUPACSNOHQASFQ-QJBWUGSNSA-N acetic acid;s-[2-[3-[[(2r)-4-[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] ethanethioate Chemical compound CC(O)=O.O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 YUPACSNOHQASFQ-QJBWUGSNSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003680 valines Chemical class 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は、新規な C標識アミノ酸及び13c標識炭素
源を使用する13C標識アミノ酸の発酵的又は酵素的製
造法に関する。DETAILED DESCRIPTION OF THE INVENTION (Industrial Application Field) The present invention relates to a method for fermentative or enzymatic production of a 13C-labeled amino acid using a novel C-labeled amino acid and a 13c-labeled carbon source.
標識アミノ酸のなかでも相隣る2つの炭素原子が共に1
3Cであるものが特に望ましい場合が多い。Among labeled amino acids, two adjacent carbon atoms are both 1
3C is often particularly desirable.
しかして、従来13c標識アミノ酸は化学的合成法によ
って製造された例はあるが、このような合成法による場
合は、アミノ酸の骨格炭素原子中、1位の炭素原子、す
なわち、カルボキシル基の炭素原子のみが130である
ものは製造されるが(例えばMSD ISOTOPE
S社)、1位の炭素原子以外の炭素原子の一部若しくは
全てが13cであるもの又は1位の炭素原子を含めて複
数の炭素原子が13cであるもの(全ての炭素原子が1
3Cであるものは除く。)の製造は極めて困難であって
、このような13C標識アミノ酸の容易な製造法の開発
が待望されている。In the past, 13c-labeled amino acids have been produced by chemical synthesis methods, but in the case of such synthesis methods, the carbon atom at position 1 among the carbon atoms in the backbone of the amino acid, that is, the carbon atom of the carboxyl group, Although only 130 is manufactured (for example, MSD ISOTOPE
Company S), those in which some or all of the carbon atoms other than the carbon atom in the 1st position are 13c, or those in which multiple carbon atoms including the carbon atom in the 1st position are 13c (all carbon atoms are 13c),
Excludes those with 3C. ) is extremely difficult to produce, and the development of an easy method for producing such 13C-labeled amino acids is eagerly awaited.
(問題点を解決するための手段)
本発明者は、炭素源として13c標識炭素源を使用する
アミノ酸発酵の研究の結果、炭素源分子の骨格炭素鎖は
発酵の代謝過程において個々の炭素原子にまで一旦は完
全に分解するとは限らず、例えば、酢酸を炭素源として
使用すると酢酸分子を構成するその炭素原子2個が代謝
過程において終始一休となって挙動すること及びグルコ
ースを炭素源として使用するとその骨格炭素鎖の一部を
構成する相連なる複数個の炭素原子が代謝過程において
一体となって挙動することを見出し、この知見に基いて
本発明を完成した。(Means for solving the problem) As a result of research on amino acid fermentation using a 13c-labeled carbon source as a carbon source, the present inventor found that the backbone carbon chain of the carbon source molecule is broken down into individual carbon atoms during the metabolic process of fermentation. For example, when acetic acid is used as a carbon source, the two carbon atoms that make up the acetic acid molecule behave at rest throughout the metabolic process, and when glucose is used as a carbon source, The inventors discovered that a plurality of consecutive carbon atoms that constitute part of the skeletal carbon chain behave as one during metabolic processes, and based on this knowledge, the present invention was completed.
因みに、アミノ酸の微生物による代謝過程は知られてい
るが(例えば、日本生化学会編[代謝マップー経路と調
節一」 (昭和55年東京化学同人発行)の第45頁に
バリン、ロイシン、イソロイシンの代謝《微生物》マッ
プが掲載されている。)、この代謝過程は極めて複雑で
あって、このようなマップをみただけでは、上記した本
発明者による知見を読み取り{qることは到底できない
。Incidentally, although the metabolic process of amino acids by microorganisms is known (for example, the metabolism of valine, leucine, and isoleucine is described on page 45 of "Metabolic Map - Pathways and Regulation 1" edited by the Japanese Biochemical Society (published by Tokyo Kagaku Dojin in 1980)). ``Microorganisms'' map has been published.) This metabolic process is extremely complex, and it is impossible to interpret the above-mentioned findings by the present inventors just by looking at such a map.
以下、本発明について逐次説明する。Hereinafter, the present invention will be explained one by one.
先ず、本発明の130標識アミノ酸の製造法について説
明する。First, the method for producing the 130-labeled amino acid of the present invention will be explained.
この製造法は発酵法(ファーメンテーション法)又は酵
素法(エンチメーション法)によるので、従って、本発
明で!11 ’>Nできるアミノ酸、すなわち、本発明
の対象アミノ酸は、パリン、ロイシン、イソロイシン、
アラニン、スレオニン、グルタミン酸、リジン、アルギ
ニン、オルニチン、フエニルアラニン、チロシン、ヒス
チジン、トリブトファン、グルタミン、セリン、ブロリ
ン等の発酵法又は酵素法によって製造可能なアミノ酸で
ある。This production method is based on a fermentation method (fermentation method) or an enzymatic method (enzymation method), so the present invention! Amino acids capable of 11'>N, that is, target amino acids of the present invention, include parine, leucine, isoleucine,
These are amino acids that can be produced by fermentation or enzymatic methods, such as alanine, threonine, glutamic acid, lysine, arginine, ornithine, phenylalanine, tyrosine, histidine, tributophane, glutamine, serine, and broline.
このようなアミノ酸の製造法自体は、使用菌、酵素源、
培地、ファーメンテーション又はエンチメーションの条
件、フ7−メンテーション又はエンチメーション終了液
からの目的アミノ酸の分離を含めて、炭素源として13
c標識炭素源を採用する他は、全て公知の方法によるこ
とができるので、この相違点のみを説明する。The production method itself for such amino acids depends on the bacteria used, the enzyme source,
13 as a carbon source, including the culture medium, fermentation or entimation conditions, and separation of the target amino acid from the fermentation or enzymation end solution.
Since all known methods can be used except for the use of the c-labeled carbon source, only this difference will be explained.
炭素源として13cIIA識炭素源を採用するといっで
も、炭素源自体はこれまた公知の炭素源でよく、ただこ
のような炭素源の少くとも一部の分子の炭素原子が少な
くとも1個が130である分子である必要があるのみで
ある。Although a 13cIIA carbon source is employed as the carbon source, the carbon source itself may also be any known carbon source, provided that at least one carbon atom in at least some of the molecules of such a carbon source is 130. It only needs to be a molecule.
それで、これについて説明すると、このような炭素源と
しては、例えば、13c標識酢酸と無標識酢酸との併用
、13C標識酢酸と無標識グルコースとの併用、 C標
識グルコースと無標識グルコースとの併用、13cta
識グルコースと無4!!Ai酢酸との併用を挙げること
ができる。13c標識炭素源分子内の炭素原子は、上記
のように少なくとも1個が13cである必要があるが、
13C標識炭素源分子内における13Cの数及び位置は
、目的とする13C標識アミノ酸が何であるかにより、
炭素源分子の骨格炭素鎖はアミノ酸発酵の代謝過程にお
いてその全部又は一部が一体となって挙り』する、とい
う前記の本発明者による知見により決めることができる
。例えば、炭素源として[1.2−1302]酢酸を使
用する場合、1及び2の両位の炭素原子が13cである
アミノ酸が相対的に多聞に生成するので、このような1
3C標識アミノ酸を得たい場合はそのような標識酢酸を
使用する。So, to explain this, such carbon sources include, for example, a combination of 13C-labeled acetic acid and unlabeled acetic acid, a combination of 13C-labeled acetic acid and unlabeled glucose, a combination of C-labeled glucose and unlabeled glucose, 13cta
Sense of glucose and no 4! ! For example, Ai can be used in combination with acetic acid. At least one carbon atom in the 13c-labeled carbon source molecule must be 13c as described above, but
The number and position of 13C in the 13C-labeled carbon source molecule depends on the target 13C-labeled amino acid.
This can be determined based on the above-mentioned finding by the present inventors that the backbone carbon chains of carbon source molecules are all or partially oxidized in the metabolic process of amino acid fermentation. For example, when [1.2-1302] acetic acid is used as a carbon source, amino acids in which both the 1st and 2nd carbon atoms are 13c are relatively frequently produced.
When it is desired to obtain a 3C-labeled amino acid, such a labeled acetic acid is used.
ファーメンテーション終了液又はエンチメーシヨン終了
液から分離したアミノ酸は、同じアミノ酸(例えば、ロ
イシンとする)であっても、種々の130標識アミノ酸
の混合物、例えばOイシンの場合は種々の13CIIA
識ロイシンの混合物であるが、前述の13c標識アミノ
酸の用途には、このような混合物のままで供することが
できる。因みに、13C標識アミノ酸分子内における1
3cの位置はNMR法によって決定でき、また13C標
識アミノ酸混合物の13Cに関する各異性体の割合もN
MR法によって測定できる。The amino acids separated from the fermentation-finished solution or the enzymation-finished solution may be the same amino acid (for example, leucine) or a mixture of various 130-labeled amino acids, such as various 13CIIA in the case of Oisine.
Although this is a mixture of labeled leucine, such a mixture can be used as is for the above-mentioned use of the 13c-labeled amino acid. Incidentally, 1 in the 13C-labeled amino acid molecule
The position of 3c can be determined by NMR method, and the proportion of each isomer with respect to 13C in the 13C-labeled amino acid mixture is also determined by NMR method.
It can be measured by MR method.
13C標識アミノ酸を発酵法又は酵素法で製造する場合
は、化学合成法で製造する場合に較べて、容易な操作で
しかも高収率に目的アミノ酸を製造できる他に、13C
標識アミノ酸分子内における13Cである炭素原子の位
置と数とが多様化するというきわめて重要な利点がある
。When producing a 13C-labeled amino acid using a fermentation method or an enzymatic method, the target amino acid can be produced with easier operation and in a higher yield than when producing it using a chemical synthesis method.
A very important advantage is that the position and number of 13C carbon atoms within the labeled amino acid molecule is diverse.
次に、1位の炭素原子(すなわち、カルボキシル基の炭
素原子)が通常の炭素原子(すなわち、12C)であっ
て、その他の炭素原子の1個以上が13Gである本発明
の新規なアミノ酸について説明する。Next, regarding the novel amino acid of the present invention, the carbon atom at position 1 (i.e., the carbon atom of the carboxyl group) is a normal carbon atom (i.e., 12C), and one or more of the other carbon atoms is 13G. explain.
このようなアミノ酸の製造法自体は前記の通りなので、
ここに付加すべき説明はない。因みに、カルボキシル基
の炭素原子のみが13Cであるアミノ酸は一般に公知で
ある。The method for producing such amino acids is as described above,
There is no explanation to add here. Incidentally, amino acids in which only the carbon atom of the carboxyl group is 13C are generally known.
以下、実施例により本発明を更に説明する。The present invention will be further explained below with reference to Examples.
実施例1(ロイシン(その1))
下記の培地Aを500mtl容フラスコに507張り込
み、ロイシン発酵菌株プレビバクテリウム・ラクトフエ
ルメンタム( B revibacterium Ia
ctofermentum) A J 3918(F
E R M − P 2516)を斜面寒天培養から
1白金耳接種し、31℃で18時間振とう培養したく種
培養)。Example 1 (Leucine (Part 1)) The following medium A was poured into a 500 ml flask, and the leucine-fermenting strain Previbacterium lactofermentum (B revibacterium Ia) was added.
ctofermentum) A J 3918 (F
One platinum loop of ERM-P 2516) was inoculated from an agar slant culture, and cultured with shaking at 31°C for 18 hours.
培地A
グルコース 3%KH2PO4
0.1%MQS0 ・7H2
0 0.04 %Fe++2ppIm
M n+ +
2p,mビオチン
10埒/jサイアミン塩酸塩 200
# / j尿素 0,3%D
L−メチオニン 0.04%大豆タンパク
塩酸加水分解液
濃縮物《総窒素3%》2、2%
pH− 6.0(KOHによる)
その後、11容ガラスジャーに下記培地Bを285IR
!張り込み、上に得た種培養液15Idを接種ら、NH
3で吐を6.25に制御しながら31℃で24時間通気
撹拌培養して湿潤菌休329得た。Medium A Glucose 3% KH2PO4
0.1%MQS0 ・7H2
0 0.04%Fe++2ppIm M n+ +
2p,m biotin
10 gram/j thiamine hydrochloride 200
# / j Urea 0.3%D
L-methionine 0.04% soybean protein hydrolyzed in hydrochloric acid concentrate (total nitrogen 3%) 2.2% pH - 6.0 (by KOH) Then, add the following medium B to an 11-volume glass jar at 285 IR.
! The seed culture solution 15Id obtained above was inoculated, and the NH
In step 3, the culture was carried out with aeration and stirring at 31° C. for 24 hours while controlling the emulsion to 6.25 to obtain a moist bacterial suspension.
培地B
グルコース
酢酸
KH2PO4
MqS0 ・7H20
Fe
Mn
DL−メチオニン
ビオチン
サイアミン塩酸塩
大豆タンパク塩酸加水分解液
10%
0.5%
0.1%
0.04 %
2DI)m
2pDlll
0.07 %
50埒/1
300埒/1
濃縮物(総窒素3%)2.2%
吐−7.0(KOHによる)
この菌体を生理食塩水にて2度洗浄した後、培地Bの、
酢酸を13c標識酢酸([1,2−”’C2]酢酸、す
なわち、炭素原子が岑で13Cである酢酸)0.5%で
置き換え、グルコース濃度を0.5%に減じ、そして大
豆タンパク塩酸加水分解液濃縮物を除いた培地(培地B
’ )に該菌体を戻し、NaOH中和を行いながら(
+)H=6.25) 31℃で24時間培養(発酵)
を行なった。その結果、し=ロイシンが、2。24g/
j蓄積していた。Medium B Glucose Acetate KH2PO4 MqS0 ・7H20 Fe Mn DL-Methionine Biotin Thiamine Hydrochloride Soy Protein Hydrochloric Acid Hydrolyzed Solution 10% 0.5% 0.1% 0.04% 2DI)m 2pDlll 0.07% 50 埒/1 300 埒/1 Concentrate (3% total nitrogen) 2.2% Vomit -7.0 (by KOH) After washing the bacterial cells twice with physiological saline, culture medium B
Replace acetic acid with 0.5% of 13c-labeled acetic acid ([1,2-'''C2]acetic acid, i.e., acetic acid where the carbon atom is 13C), reduce the glucose concentration to 0.5%, and soybean protein hydrochloride. Medium excluding hydrolyzate concentrate (medium B
), and while neutralizing with NaOH (
+)H=6.25) Culture at 31°C for 24 hours (fermentation)
I did it. As a result, leucine was 2.24g/
j was accumulating.
この培養液を遠心分tIi機にて菌体を分離した後、イ
オン交換樹脂法を用いて単離′R興して538FJのL
一ロイシンを得た。After separating the bacterial cells from this culture using a centrifugal tII machine, the cells were isolated using an ion exchange resin method and 538FJ L
One leucine was obtained.
このL一ロイシンを分析したところ、1位の炭素原子(
カルボキシル基の炭素原子)と2位の炭素原子(α位の
炭素原子)との両者のみが共に130標識されたし一ロ
イシンが75%であった。When this L-leucine was analyzed, the carbon atom at the 1st position (
Only both the carbon atom of the carboxyl group) and the carbon atom at the 2-position (the carbon atom at the α-position) were labeled with 130, and monoleucine accounted for 75%.
前記培地において、炭素源として酢酸は13C無標識の
ものを使用し、グルコースは13c標識のものを使用し
て発酵を行ったところ、1及び2の両位の炭素原子以外
の炭素原子が全て13C標課されたし−ロイシンが20
%であった。In the above medium, when fermentation was carried out using 13C-unlabeled acetic acid and 13C-labeled glucose as carbon sources, all carbon atoms other than the carbon atoms at both positions 1 and 2 were converted to 13C. It was marked - Leucine is 20
%Met.
これらの結果から、L一ロイシン生成の代謝過程におい
て、酢酸分子の両炭素原子は少なくとも一部の酢酸にお
いては一体となって挙動することが理解ざれる。From these results, it is understood that in the metabolic process of producing L-leucine, both carbon atoms of the acetic acid molecule behave as one in at least some acetic acid.
実施例2(ロイシン(その2)) 種培養を実施例1におけると全く同様にして行なった。Example 2 (Leucine (Part 2)) Seed culture was carried out exactly as in Example 1.
その復、11容ガラスジャーに下記培地Cを285威張
り込み、上に得た種培養液を15m接種し、NaOHで
pHを6.25ニ制御しながら31℃テ24時間通気撹
拌培養して湿潤菌体を3247得た。Then, fill an 11-volume glass jar with 285 m of the following medium C, inoculate 15 m of the seed culture solution obtained above, and culture with aeration at 31°C for 24 hours with aeration and stirring while controlling the pH to 6.25 with NaOH. 3247 bacterial cells were obtained.
培地C
グルコース
酢酸
尿素
KH2 PO4
MQS0 ・7H20
10%
0.5%
0.1%
0.1%
0.04 %
Fe″+
Mn″“
DL−メチオニン
ビオチン
サイアミン塩酸塩
大豆タンパク塩酸加水分解液
濃縮物(総窒素3%)
ph= 7.0(KOHによる)
この菌体を生理食塩水にて2度洗浄した後、培地Cの、
酢酸を実施例1で使用したと同じ13c標識酢fft
0. 25%で置き換え、グルコース濃度を0,75%
に変え、大豆タンパク塩酸加水分解液濃縮物を除いた培
地(培地C’ )に該菌体を戻し、NaOH中和を行い
ながら(1)H = 6.25) 31℃テ24時間培
養(発N)を行った。その結果、L一ロイシンが3.0
19/II蓄積していた。Medium C Glucose Acetate Urea KH2 PO4 MQS0 ・7H20 10% 0.5% 0.1% 0.1% 0.04% Fe"+ Mn"" DL-Methionine Biotin Thiamine Hydrochloride Soy Protein Hydrochloric Acid Hydrolyzate Concentrate (3% total nitrogen) pH = 7.0 (by KOH) After washing the bacterial cells twice with physiological saline,
Acetic acid was the same 13c-labeled vinegar fft used in Example 1.
0. 25%, glucose concentration 0,75%
The cells were then returned to the medium (medium C') from which the soybean protein hydrolyzate concentrate was removed, and cultured (1) at 31°C for 24 hours while neutralizing with NaOH (1) H = 6.25). N) was performed. As a result, L-leucine is 3.0
19/II had accumulated.
この培養液を実施例1におけると同様に処理し2.2% 2ppm 2ppffl 0.07 % 50埒/1 300埒/p て 722#19のL一ロイシンを得た。This culture solution was treated in the same manner as in Example 1, and 2.2% 2ppm 2ppffl 0.07% 50 埒/1 300 埒/p 722#19 L-leucine was obtained.
このL−ロイシンの分析結果は、1及び2の両位の炭素
原子のみが同時に13c標識されたL一口イシンが50
%であった。The analysis results for L-leucine show that L-leucine is 13c-labeled at both the 1st and 2nd carbon atoms at the same time.
%Met.
前記培地において、炭素源として酢酸は13c無f!I
のものを使用し、グルコースは13C標識のものを使用
して発酵を行ったところ1及び2の両位の炭素原子以外
の炭素原子が全て13c標識されたし一ロイシンは45
%であった。In the above medium, acetic acid is used as a carbon source with 13c no f! I
When fermentation was carried out using 13C-labeled glucose, all carbon atoms other than the carbon atoms at both positions 1 and 2 were labeled with 13C, and leucine was 45
%Met.
実施例3(バリン(その1))
下記の培地Dを500ae容フラスコに50m張り込み
、バリン発酵菌株プレビバクテリウム・ラクトフエルメ
ンタム( B reVibacteritll1Iac
tofern+entum)AJ 3450(FER
M−P1963)を1白金耳接種し、31℃で13時間
振どう培養した(種培養)。Example 3 (Valine (Part 1)) A 500 ae flask was filled with 50 m of the following medium D, and the valine fermenting strain Previbacterium lactofermentum (B reVibacteritll1Iac
tofern+entum) AJ 3450 (FER
One platinum loop of M-P1963) was inoculated and cultured with shaking at 31°C for 13 hours (seed culture).
培地D
培地E
?ルコース 3%尿素
0.3%KH2 PO4
0.1%MaSO − 7H2.0
0.04 tx,F e+ +
2,,■Mn++ 2
ppmOL−メチオニン 0. 01%ビ
オチン 10Jlg/41サイア
ミン塩酸塩 200巧/ρ大豆タンパク塩
酸加水分解液
濃縮物(総窒jPj3%》 4%1)H=
6.5(KOHによる》
その後、1p容ガラスジャーに下記培地Eを285一張
り込み、上に得た種培養液を151R!!接種し、NH
3で川を6.5に制御しながら31℃で48時間通気撹
拌培養して湿潤菌体を23g得た。Medium D Medium E? Lucose 3% urea
0.3%KH2 PO4
0.1%MaSO-7H2.0
0.04 tx, F e+ +
2,,■Mn++ 2
ppmOL-Methionine 0. 01% biotin 10 Jlg/41 thiamine hydrochloride 200/ρ soy protein hydrochloric acid hydrolyzate concentrate (total nitrogen 3%》 4%1) H=
6.5 (by KOH) After that, fill a 1p glass jar with 285 of the following medium E, inoculate 151R!! of the seed culture solution obtained above, and inoculate NH
The culture was carried out with aeration at 31° C. for 48 hours while controlling the flow rate to 6.5 in Step 3 to obtain 23 g of wet bacterial cells.
グルコース 13%酢11Q
0.3%硫酸アンモニウム
2%KH2 PO4
0.1%MQS0 ・7H20 0
.04%F e 2pp
mM n 2ppmDL
−メチオニン 0.06%ビオヂン
50#/jサイアミン塩酸塩
200埒/fJ大豆タンパク塩酸加水分解液
濃縮物(総窒素3%) 3%+1H= 6.
5(KOHによる)
この菌体を生理食塩水にて2度洗浄した後、培地Eの、
グルコース13%と酢酸0.3%を13c標識酢酸0.
5%及び無標識グリコース0.5%で置き換え、大豆タ
ンパク塩酸加水分解液濃縮物を除いた培地(培地E”)
に該菌休を戻し、NaOH中和を行いながら(1)H
= 6.5)31℃で48時間培養を行った。その結果
、L−パリンが1.79/41蓄積していた。Glucose 13% Vinegar 11Q
0.3% ammonium sulfate
2%KH2 PO4
0.1%MQS0 ・7H20 0
.. 04%Fe 2pp
mM n 2ppmDL
-Methionine 0.06% biodine
50#/j thiamine hydrochloride
200 g/fJ soy protein hydrolyzate concentrate (total nitrogen 3%) 3% + 1H = 6.
5 (by KOH) After washing the bacterial cells twice with physiological saline,
13% glucose and 0.3% acetic acid were combined with 13c-labeled acetic acid 0.
5% and unlabeled glycose 0.5%, and removed the soy protein hydrolyzate concentrate (medium E")
Return the bacterial suspension to (1) H while neutralizing with NaOH.
= 6.5) Culture was performed at 31°C for 48 hours. As a result, L-parin was accumulated at 1.79/41.
この培養液を実施例1におけると同様に処理して510
IIlgのL−バリンを得た。This culture solution was treated in the same manner as in Example 1 to give 510
Illg of L-valine was obtained.
このし−バリンを分析したところ、1位の炭素原子力ル
ボキシル基の炭素原子》と2位の炭素原子(α位の炭素
原子)との両者のみが共に13C標識されたL−バリン
が24%であった。また、3位の炭素原子(β位の炭素
原子)と4位の炭素原子(γ位の炭素原子)との両者の
みが共に13C45j!識されたL−バリンが24%で
あった。また、全ての炭素原子が無標識のL−バリンが
29%であった。Analysis of this valine revealed that 24% of L-valine was labeled with 13C at both the 1st-position carbon atom of the carboxyl group and the 2nd-position carbon atom (alpha-position carbon atom). there were. Also, only the carbon atom at the 3rd position (the carbon atom at the β position) and the carbon atom at the 4th position (the carbon atom at the γ position) are both 13C45j! The detected L-valine was 24%. Furthermore, L-valine in which all carbon atoms were unlabeled was 29%.
実施例4(ロイシン(その3))
実施例1におけると同様にして、A及びB両培地を使用
して培養して得たプレビバクテリウム・ラクトフェルメ
ンタムA J 3918の菌体を生理食塩水にて2度洗
浄した後、培地Bのグルコースを99% C[U
C]標識したグルコースを重量比35%含むグルコース
209で置き換え、さらに大豆タンパク塩酸加水分解液
濃縮物を除いた培地(培地B″)に該菌体を戻し、NH
3中和を行いながらpi−1 7.0 、31℃で38
時間培養(発酵)した。その結果、L一ロイシンガ17
.4g/l蓄積していた。Example 4 (Leucine (Part 3)) In the same manner as in Example 1, the cells of Previbacterium lactofermentum A J 3918 obtained by culturing using both medium A and B were dissolved in physiological saline. After washing twice with
C] The labeled glucose was replaced with glucose 209 containing 35% by weight, and the bacterial cells were returned to the medium (medium B″) in which the soybean protein hydrolyzate concentrate was removed.
3 pi-1 7.0 while performing neutralization, 38 at 31℃
Cultured (fermented) for hours. As a result, L-Leusinga 17
.. It had accumulated 4g/l.
この培養液から菌体を遠心分離により除き、イオン交換
.樹脂法を用いて単m精製した3660rItgのLロ
イシンを得た。Bacterial cells are removed from this culture solution by centrifugation, and ion exchange is performed. L-leucine of 3660 rItg was purified using the resin method.
このL一ロイシンの130 − N M Rスペクトル
を測定したところ、グルコースを炭素源とする生合成経
路を反映した不均一な130分布を持つことがわかった
。すなわち、このNMRスペクトルの回析の結果、得ら
れたし−ロイシンは炭素源として培地中に添加した非標
識および13c標識グルコース由来の炭素数2を持つ3
個の構造単位(ブロツク)から構成されていることが判
明した。この3個のブロックは(1)[Go.Gα];
(2)[Cβ,Cδ ]:(3)[Cγ,Cδ2]であ
る。When the 130-NMR spectrum of this L-leucine was measured, it was found to have a non-uniform 130 distribution reflecting the biosynthetic pathway using glucose as a carbon source. That is, as a result of diffraction of this NMR spectrum, it was obtained that - leucine is 3 with carbon number 2 derived from unlabeled and 13c-labeled glucose added to the medium as a carbon source.
It was found that it is composed of several structural units (blocks). These three blocks are (1) [Go. Gα];
(2) [Cβ, Cδ]: (3) [Cγ, Cδ2].
ここにCOはカルボキシル基の炭素原子を意味し、Cα
は2位の炭素原子を意味し、その伯の位置の炭素原子に
ついては下記構造式を参照のこと。Here, CO means a carbon atom of a carboxyl group, and Cα
means the carbon atom at the 2nd position, and for the carbon atom at the 2nd position, please refer to the structural formula below.
(Cδ2) NH2
標識グルコース起源のブロック内は85%に及ぶ高い1
3C標識率を持つが、任意の2つのブロックが同時に1
3C標識グルコースに由来するブロックとなる確率は、
統計的に予想される限り、約35%の値である。指摘す
るまでもないが、標識ブロックが同一分子に複数含まれ
る確率は、標識グルコースの混合比(本実施例では35
%)を変化させることにより容易に制御可能である。(Cδ2) The block originating from NH2-labeled glucose is as high as 1 up to 85%.
It has a 3C labeling rate, but any two blocks are 1 at the same time.
The probability that the block is derived from 3C-labeled glucose is
As far as statistically expected, the value is about 35%. Needless to point out, the probability that multiple labeled blocks are included in the same molecule is determined by the mixing ratio of labeled glucose (in this example, 35
%) can be easily controlled by changing.
以下の実施例においては、このようにして得られる生合
成経路を反映して不均一に13CFj識されたアミノ酸
を35%13c“′ブロック標識″アミノ酸と呼ぶこと
にする。即ち、本実施例でえられたL一ロイシンは35
%13cブロック標識L一ロイシンである。In the following examples, amino acids that are heterogeneously labeled 13CFj will be referred to as 35% 13c "'block labeled" amino acids, reflecting the biosynthetic pathway obtained in this way. That is, the L-leucine obtained in this example is 35
%13c block labeled L-leucine.
13cブロック標識ロイシンの最も重要な特徴は、2個
のプロキラルメチメ基を立体選択的に標識することが可
能な点である。Cδ1及びCδ2はそれぞれpro−3
及びpro−Rメチル基炭素に相当ずる。ブロック標識
の結果、pro−Rメチル基炭素のNMRジクナルは強
いダブレットを、proSメチル基炭素のそれは強いシ
ングレットとじて現れ、容易に区別がつく。このような
立体的選択的に標識されたロイシンは有機合成化学的方
法によっては合成が極めて困難であったが、本発明の方
法により安価、簡便、多量調整技術が確立することにな
り、蛋白質のNMRスペクトル中のロイシン残塁のメチ
ルシグナルの立体特異的帰属、ロイシン側鎖シグナルの
一括帰属などNMRによる蛋白質の立体構造の決定技術
に欠くことのできない重・要な用途をもつ。The most important feature of 13c block-labeled leucine is that two prochiral methime groups can be stereoselectively labeled. Cδ1 and Cδ2 are respectively pro-3
and pro-R methyl group carbon. As a result of the block labeling, the NMR diknal of the pro-R methyl group carbon appears as a strong doublet, and that of the proS methyl group carbon appears as a strong singlet, making them easily distinguishable. Although it has been extremely difficult to synthesize such stereoselectively labeled leucine using organic synthetic chemical methods, the method of the present invention establishes a cheap, simple, and large-quantity preparation technique, which enables protein synthesis. It has important uses that are indispensable for the technology for determining the three-dimensional structure of proteins by NMR, such as stereospecific assignment of methyl signals of leucine residues in NMR spectra and batch assignment of leucine side chain signals.
実施例5(ロイシン等(その1))
実施例1におけると同様にして、A及びB両培地を使用
して培養して得たプレビバクテリウム・ラクトフエルメ
ンタムA J 3918の菌体を生理食塩水にて2度洗
浄した後、培地Bのグルコースを99% C’[1−1
3G]標識したグルコース20gで置き換え、さらに大
豆タンパク塩酸加水分解液濃縮物を除いた培地(培地B
” ’ )に該菌体を戻し、NH3中和を行いながらp
H7.0 , 31℃で38時間培!!(発酵)した。Example 5 (Leucine etc. (Part 1)) In the same manner as in Example 1, the cells of Previbacterium lactofermentum A J 3918 obtained by culturing using both medium A and B were dissolved in physiological saline. After washing twice with water, the glucose in medium B was reduced to 99% C'[1-1
3G] The medium was replaced with 20 g of labeled glucose and the soybean protein hydrolyzate concentrate was removed (Medium B
” ), and while neutralizing NH3, p.
H7.0, culture at 31℃ for 38 hours! ! (fermented).
その結果、L一ロイシンが20、5ク/fJ蓄積してい
た。As a result, L-leucine was accumulated at 20.5 k/fJ.
この培養液から菌休を遠心分離により除き、イオン交換
樹脂法を用いて単離精製して4840mgのしーロイシ
ンを得た。Leucine was removed from this culture solution by centrifugation, and isolated and purified using an ion exchange resin method to obtain 4,840 mg of leucine.
このL一ロイシンの13C−NMRスペクトルを測定し
たところ、13c標識位置はCα.Cδ1及びCδ2の
3個所に限られていることがわかった。When the 13C-NMR spectrum of this L-leucine was measured, the 13c labeling position was at Cα. It was found that it was limited to three locations, Cδ1 and Cδ2.
標識率は約50%程度であったが、このような位置選択
的標識ロイシンを化学合成的に調製することは極めて困
難であり、その点本発明の方法は際立った利点がある。Although the labeling rate was about 50%, it is extremely difficult to chemically synthesize such regioselectively labeled leucine, and the method of the present invention has a distinct advantage in this respect.
同様な実験をし−バリン、し−イソロイシンについて行
ったが、パリン、イソロイシンともにCγ とCγ2の
みに高濃度(約50%)の C標識が見出された。A similar experiment was conducted for valine and isoleucine, but high concentrations (approximately 50%) of C label were found only in Cγ and Cγ2 for both palin and isoleucine.
ここに、L−バリン及びL一ロイシンの炭素原子の位置
については下記構造式を参照のこと。Here, please refer to the following structural formula for the positions of carbon atoms of L-valine and L-leucine.
(Cδ) (Cγ1)
当然のことながら、1位の炭素以外に13c標識された
グルコース類を用いれば、他の特定部位を標識したアミ
ノ酸類が調製可能である。また、次ド
の実施例め述べるアミノ酸類についても同様な手法が適
用可能である。(Cδ) (Cγ1) Naturally, by using glucose labeled with 13c at a carbon other than the 1st position, amino acids labeled at other specific positions can be prepared. Further, the same method can be applied to the amino acids described in the next example.
実施例6(ロイシ等(その2))
実施例1におけると同様にして、A及びB両培地を使用
して培養して得たプレビバクテリウム・ラクトフエルメ
ンタムA J 3918の菌体を生理食塩水にて2度洗
浄した侵、培地8のグルコースを36% C [U−1
3G] 20SFで置き換え、さらに大豆タンパク塩酸
加水分解液溌縮物を除いた培地(培地Brrrt>に該
菌体を戻し、NH3中和を行いながらpH7.0 .
31℃で38時間培養(発酵)した。その結果、L一ロ
イシンが17.4g/Jl蓄積していた。Example 6 (Leusi et al. (Part 2)) Cells of Previbacterium lactofermentum A J 3918 obtained by culturing using both A and B medium in the same manner as in Example 1 were added to physiological saline. After washing twice with water, the glucose in medium 8 was added to 36% C [U-1
3G] 20SF, and the cells were returned to a medium (medium Brrrt) from which the soybean protein hydrolyzate hydrolyzate was removed and the pH was adjusted to 7.0.3G while neutralizing NH3.
Culture (fermentation) was carried out at 31° C. for 38 hours. As a result, L-leucine was accumulated at 17.4 g/Jl.
この培養液から菌体を遠心分離により除き、イオン交換
樹脂法を用いて単離精製して4070〜のし−ロイシン
を得た。The bacterial cells were removed from this culture solution by centrifugation, and isolated and purified using an ion exchange resin method to obtain Noshi-Leucine 4070.
このL一ロイシンの130 − N M Rスペクトル
を測定したところ、36%[Ll−13C]L−ロイシ
ンが生成していることが判明した。When the 130-NMR spectrum of this L-leucine was measured, it was found that 36% [Ll-13C]L-leucine was produced.
従来は均一に13c標識したロイシンは標識蛋白質の加
水分解物からの分離によるしかなかったが、本発明の方
法ではOイシン以外にもバリン、イソロイシン、アラニ
ン、グルタン酸、グルタミン、リジン、アルギニン、オ
ルニチリン、ヒスチジン、トリブトファン、フエニルア
ラニン、チOシン、スレオニンなどグルコースなど標識
した糖源から微生物発酵が可能なアミノ酸であれば、そ
の均一13C標識体を必要な母だけ調製することが可能
な点が、特に優れている。Conventionally, uniformly 13c-labeled leucine could only be obtained by separating it from the hydrolyzate of labeled protein, but in the method of the present invention, in addition to O-isoleucine, valine, isoleucine, alanine, glutanic acid, glutamine, lysine, arginine, and ornithilline can be obtained. , histidine, tributophane, phenylalanine, thiosine, threonine, and other amino acids that can be microbially fermented from labeled sugar sources such as glucose, the point is that uniform 13C-labeled forms of only the necessary base can be prepared. , is particularly good.
実施例7(プロリン等)
下記の培地Fを500d容フラスコに50d張り込み、
ブロリン発酵菌株プレビバクテリウム・ラクトフエルメ
ンタム( 3 revibacteriunIacto
fermentua+) A J 11225 ( F
E R M P − 4370)を斜面寒天培養から
1白金耳接種し、30℃で18時間振とう培養した(種
培養)。Example 7 (Proline etc.) Pour 50 d of the following medium F into a 500 d flask,
Brolin-fermenting strain Previbacterium lactofermentum (3 revibacterium lactofermentum)
fermentua+) A J 11225 (F
One platinum loop of ERM P-4370) was inoculated from the agar slant culture, and cultured with shaking at 30°C for 18 hours (seed culture).
培地F
グルコース 2%KH2PO4
0.1%MgSO4 ・7H2
0 . 0.04%Fe ”
2ppmM n ”
21)I)Illビオチン
50i/Nサイアミン塩酸塩
200IJ!J/ j尿素
O、25%大豆タンパク塩酸加水分解液
淵縮物(総窒素3%)2.2%
1)H= 7.0(KOHによる)
その後、1p容ガラスジャーに下記培地Gを270歳張
り込み、上に得た種培養液301!l!を接種し、NH
3でpHを7.0に制御しながら30℃で24時間通気
撹拌培養して湿潤菌体14g得た。Medium F Glucose 2% KH2PO4
0.1%MgSO4 ・7H2
0. 0.04%Fe”
2ppmMn”
21) I) Ill Biotin
50i/N thiamine hydrochloride
200 IJ! J/j urea
O, 25% soybean protein hydrochloric acid hydrolyzate condensate (3% total nitrogen) 2.2% 1) H = 7.0 (by KOH) Then, fill a 1p glass jar with the following medium G for 270 years. Seed culture solution obtained in 301! l! inoculated with NH
3 and cultured with aeration at 30° C. for 24 hours while controlling the pH to 7.0 to obtain 14 g of wet bacterial cells.
培地G
グルコース 10%硫安
1.0%硫安
6%KH2 P 04
0.1%MQSO4− 7H,,0 0.
04 %Fe゛2pDIII
Mn++2ppl
Dしーメチオニン o. oy%どオチ
ン 450tty/Jサイアミ
ン塩酸塩 1000埒/Jl大豆タンパク
塩酸加水分解液
濃縮物(総窒素3%) 0.2d/dlp
H= 7.0(KOHによる)
この菌体を生Ig!食塩水にて2度洗浄した侵、培地G
のグルコース(100g/ρ》をグルコース(5g/j
!)と99% C[2−”’CI酢酸(5g/1)の糖
酢混合物に変え、さらに大豆タンパク塩酸加水分解液濃
縮物を除いた培地《培地G’ )に該菌体を戻し、NH
3中和を行いながらDH7.0 . 30℃で16時間
培養(発酵)した。その結果、L−プロリンが2.8g
/41蓄積していた。Medium G glucose 10% ammonium sulfate
1.0% ammonium sulfate
6%KH2P 04
0.1%MQSO4-7H,,0 0.
04%Fe゛2pDIII Mn++2ppl D-Methionine o. oy% Dootin 450tty/J Thiamine Hydrochloride 1000 tsumu/Jl Soybean Protein Hydrochloric Acid Hydrolyzate Concentrate (Total Nitrogen 3%) 0.2d/dlp
H = 7.0 (by KOH) Live Ig this bacterial body! Culture medium G washed twice with saline
of glucose (100g/ρ) to glucose (5g/j
! ) and 99% C[2-'''CI acetic acid (5 g/1) in a sugar-vinegar mixture, and the soybean protein hydrolyzate hydrolyzate concentrate was removed (Medium G'), and the bacterial cells were returned to NH
DH7.0 while performing 3 neutralization. It was cultured (fermented) at 30°C for 16 hours. As a result, 2.8g of L-proline
/41 had accumulated.
この培養液から菌体を遠心分離により除き、イオン交換
樹脂法を用いて、単離精製して700IngのL−ブロ
リンを15?た。The bacterial cells were removed from this culture solution by centrifugation, and 700 Ing of L-brolin was isolated and purified using the ion exchange resin method. Ta.
このL−ブロリンを”’C − N M Rスペクトル
により分析したところ、Cα.Cβ及びCγに顕著な1
3 cの分布が見られ、特にCγは強く標識されていた
。このようなCγの標識体はNMRスペクトルによりタ
ンパク質中のブロリンを含んだベブチド結合のシス・ト
ランス決定に有用である。When this L-brolin was analyzed by C-NMR spectrum, it was found that 1 was found to be prominent in Cα, Cβ and Cγ.
A distribution of 3c was observed, and Cγ was particularly strongly labeled. Such a Cγ label is useful for determining cis/trans of broline-containing bebutide bonds in proteins by NMR spectroscopy.
ここに、ブロリンの炭素原子の位置については下記構造
式参照のこと。Here, please refer to the structural formula below for the position of the carbon atom of broline.
(Cγ) (Cβ)
CH2−CH2
+ 1 (Co)CH
CH−COOH
(Cδ)\ /(Cα)
N
H
一方、上の実験で99%13C[2−130]酢酸(5
g/fi ) jE: [1−13Cl 酢mテ置1
!−換エルコとにより、CδとCoのみを高度に標識し
たL−ブロリンを調製することも容易である。また、酢
酸あるいはグルコースと[1.2− 02]酢酸を混
合した酢酸培地又は糖酢培地で置き換えることにより、
Cブロック標FIiL−ブ0リンを生成させることが
できた。この場合ブロック構成は(1)[Co] :(
2)[Cα.Cβ] : (3)[C7.Cδ]及び(
1)[CO,Cαコ:(2)[Cβ];(3)[Cγ,
Cδ]の2通りであり、両者は同じ確率で起こっていた
。(Cγ) (Cβ) CH2−CH2 + 1 (Co)CH
CH-COOH (Cδ)\ /(Cα) NH On the other hand, in the above experiment, 99% 13C[2-130]acetic acid (5
g/fi) jE: [1-13Cl vinegar mte 1
! It is also easy to prepare L-brolin in which only Cδ and Co are highly labeled by -Erco. In addition, by replacing with an acetic acid medium or a sugar vinegar medium containing a mixture of acetic acid or glucose and [1.2-02] acetic acid,
C-block labeled FIiL-burin could be produced. In this case, the block configuration is (1) [Co] :(
2) [Cα. Cβ] : (3) [C7. Cδ] and (
1) [CO, Cα: (2) [Cβ]; (3) [Cγ,
Cδ], and both occurred with the same probability.
このような酢酸のみ或いは酢酸とグルコースの混合物(
糖酢培地)を利用するブロック標識法はL一ロイシンの
[CO,Cα]が酢酸起源(アセチルCoA)であるこ
とを利用する標識法(実施例1)を除けば酢酸を高い効
率で責化しアミノ酸に変質しつるアミノ酸発酵系のみ適
用が限られる。Such acetic acid alone or a mixture of acetic acid and glucose (
The block labeling method using a sugar-acetate medium (sugar-acetate medium) does not repel acetic acid with high efficiency, except for the labeling method (Example 1) that utilizes the fact that [CO, Cα] of L-leucine originates from acetic acid (acetyl-CoA). Application is limited to amino acid fermentation systems that are transformed into amino acids.
これらのアミノ酸はグルタン酸、グルタミン、リジン、
アルギニン、オルニチリン、スレオニン、ブロリンの7
種類である。これらのアミノ酸の位置特異的13c標識
体、均一標識体或いはブロック標識体を比較的安価な原
料である13C標識酢酸源として用いて得る本発明方法
は経済性が極めて優れている。These amino acids are glutaric acid, glutamine, lysine,
Arginine, ornityline, threonine, and broline.
It is a kind. The method of the present invention, which uses position-specific 13c-labeled, uniformly labeled or block-labeled amino acids as a 13C-labeled acetic acid source, which is a relatively inexpensive raw material, is extremely economical.
実施例8(イソロイシン)
下記の培地Hを5001nt!容フラスコに50耐張り
込み、イソロイシン発酵菌株プレビバクテリウム・ラク
トフェルメンタム( [3 revibacteriu
m factorern+entun+) A J 3
689(F E R M P − 2436)を斜面寒
天培養から1白金耳接種し、31℃で18時間振どう培
養したく種培養)。Example 8 (Isoleucine) 5001 nt of the following medium H! Fill a 50 ml capacity flask with isoleucine-fermenting strain Previbacterium lactofermentum ([3 revibacterium
m factorern+entun+) A J 3
One platinum loop of 689 (FERMP-2436) was inoculated from an agar slant culture, and cultured with shaking at 31°C for 18 hours (seed culture).
培地H
グルコース 3%KH,2 PO
4 0.1%MQSO − 7
H20 0.04 %Fe++2ppli
Mn++2ppIl
ビオチン 200IIg/ j
サイアミン塩酸塩 300埒/Jl酢酸
アンモニウム 0.3%大豆タンパク塩酸
加水分解液
濃縮物(総窒素3%) 6%pH= 8.0
(NaOHによる)
その後、1g容ガラスジャーに下記培地!を2851d
張り込み、上に得た種培養液15mを接種し、NH3で
吐を7.3に制御しながら31℃で24時間通気撹拌培
養して湿潤菌体149得た。Medium H Glucose 3% KH, 2 PO
4 0.1%MQSO-7
H20 0.04%Fe++2ppli Mn++2ppIl Biotin 200IIg/j
Thiamine hydrochloride 300 g/Jl Ammonium acetate 0.3% soy protein hydrochloric acid hydrolyzate concentrate (total nitrogen 3%) 6% pH = 8.0
(By NaOH) Then, add the following medium to a 1g glass jar! 2851d
15 ml of the seed culture obtained above was inoculated, and cultured with aeration and stirring at 31° C. for 24 hours while controlling the emulsion to 7.3 with NH3 to obtain 149 wet bacterial cells.
培地■
グルコース
10%
1v!t酸アンモニウム
1.5%
KH2PO4
MoSO ・7H,0
F e+ +
Mn
ビオチン
サイアミン塩酸塩
大豆タンパク塩酸加水分解液
濃縮物(総窒素4.2%)
pH= 4.2(KOHによる》
0.1%
0.04 %
2ppm
2ppm
50u9/ IQ
3000埒/fJ
1.2%
この菌体を生理食塩水にて2度洗浄した後、培地Iの中
のグルコースを99%13C標識体を重量比33%含む
グルコース209で置き換え、さらに大豆タンパク塩酸
加水分解液濃縮物を除いた培地(培地1’ )に該菌休
を戻し、NH.中和を行いながらpH 7.3、31℃
で38時間培養(発酵)した。その結果、L−イソロイ
シンが1.39/j蓄積していた。Medium■ Glucose 10% 1v! Ammonium t-acid 1.5% KH2PO4 MoSO ・7H,0 Fe+ + Mn Biotin thiamine hydrochloride Soy protein hydrochloric acid hydrolyzate concentrate (total nitrogen 4.2%) pH = 4.2 (by KOH) 0.1 % 0.04% 2ppm 2ppm 50u9/IQ 3000m/fJ 1.2% After washing the bacteria twice with physiological saline, the glucose in medium I was reduced to 99% and the 13C-labeled substance was 33% by weight. The culture medium was replaced with glucose 209 containing glucose 209, and the soybean protein hydrolyzate hydrolyzate concentrate was removed (medium 1').
It was cultured (fermented) for 38 hours. As a result, L-isoleucine was accumulated at 1.39/j.
この培養液から菌体を遠心分離により除き、イオン交換
樹脂法を用いて単離精製して3500#+9のL一イソ
ロイシンを得た。このし−イソロイシンを13C −
N M Rスペクトルにより分析したところ、実施例5
で説明したように、13C標識グルコースに由来する1
3C標識されたブロックから構成される13Cブロック
標識体であることが判明した。LーイソOイシンの場合
も、L一ロイシンの場合と同様に、3つのグルコースか
ら由来する独立な3ブロックが見出された。(1)[C
o.Cα.Cγ ]:(2)[Cβ.Cγ2];(3)
[Cδ]。The bacterial cells were removed from this culture solution by centrifugation, and isolated and purified using an ion exchange resin method to obtain 3500#+9 L-isoleucine. This is - isoleucine 13C -
As analyzed by NMR spectrum, Example 5
As explained in , 1 derived from 13C-labeled glucose
It turned out to be a 13C block labeled substance composed of 3C labeled blocks. In the case of L-isoOisine, as in the case of L-leucine, three independent blocks derived from three glucoses were found. (1) [C
o. Cα. Cγ]: (2) [Cβ. Cγ2]; (3)
[Cδ].
同一グルコース由来の複数の炭素を持つブロツク(ブロ
ック(1)及び(2))においては85%程度の高濃度
に13CI!識されたブロックが約35%程度含まれて
いることが明らかである。このブロック13cJI標識
し−イソロイシンに関しても蛋白質NMRなと広範な用
途が見出され得る。In blocks with multiple carbons derived from the same glucose (blocks (1) and (2)), the concentration was as high as 85% with 13 CI! It is clear that approximately 35% of the blocks are identified. This block 13cJI-labeled isoleucine may also find wide applications in protein NMR.
実施例9(バリン(その2))
実施例3におけると同様にして、D及びE両培地を使用
して培養して得たプレビバクテリウム・ラクトフエルメ
ンタムAJ3450の菌休を生理食塩水にて2度洗浄し
た後、培地E中のグルコースを炭素原子が全て13Cで
あるグルコースを非標識グルコースに約35%の割合で
混合したちの103で置き換え、さらに大豆タンパク塩
酸加水分解液濃縮物を除いた培地(培地E″)に該菌体
を戻し、NH3中和を行いながら吐6.5、31℃で3
8時間培養《発vJ》シた。その結果、L−バリンが1
7.39/ρ蓄積していた。Example 9 (Valine (Part 2)) Previbacterium lactofermentum AJ3450 obtained by culturing in both D and E medium in the same manner as in Example 3 was cultured in physiological saline. After washing twice, the glucose in medium E was replaced with 103, which is a mixture of glucose whose carbon atoms are all 13C and unlabeled glucose at a ratio of about 35%, and the soybean protein hydrolyzate concentrate was removed. The cells were returned to the culture medium (medium E'') and incubated at 31°C for 6.5 hours while neutralizing NH3.
Cultured for 8 hours. As a result, L-valine was 1
7.39/ρ had accumulated.
この培養液から菌休を遠心分離により除き、イオン交換
樹脂法を用いて単離精製して4240■のし−バリンを
得た。Bacillus valine was removed from this culture solution by centrifugation, and isolated and purified using an ion exchange resin method to obtain 4240 ml of Noshivaline.
このL−バリンを13C − N M Rスペクトルに
より分析したところ、実施例5で説明したように、13
c標識グルコースに由来する,、 C標識された独立な
2ブロックから構成されるブロック標識体であることが
判明した。し−バリンの場合もしーロイシン、し−イソ
ロイシンの場合と同様に、2つのグルコースから由来す
る独立な2ブロックが見出された:(1)[GO.Cr
y,Cγ1];(2)[Cβ,Cγ2]。Cγ1及びC
γ2はそれぞれブロキラルなメチルシグナルであり、p
ro−S及びpro−Rに相当する。同一グルコース由
来の複数の炭素を持つこれら2つのブロックにおいては
、85%程度の高澹度13c標識されたブロックが約3
5%程度含まれていることが明らかである。When this L-valine was analyzed by 13C-NMR spectrum, as explained in Example 5, 13
It was found that it is a block-labeled substance composed of two independent C-labeled blocks derived from c-labeled glucose. In the case of valine, as in the case of leucine and isoleucine, two independent blocks derived from two glucoses were found: (1) [GO. Cr
y, Cγ1]; (2) [Cβ, Cγ2]. Cγ1 and C
γ2 is a brochiral methyl signal, p
Corresponds to ro-S and pro-R. In these two blocks with multiple carbons derived from the same glucose, the block with a high degree of 13c labeling of about 85% has about 3
It is clear that it contains about 5%.
このブロック13c標識L−バリンに関しても最も信頼
性のおけるメチル基シグナルの立体的的帰属を始め、蛋
白質NMRなどに大きな用途が拓けている。This block 13c-labeled L-valine also has great applications in protein NMR, including the most reliable steric assignment of methyl group signals.
Claims (2)
とを特徴とするアミノ酸。但し、全ての炭素原子が^1
^3Cであるもの及びカルボキシル基の炭素原子のみが
^1^3Cであるものを除く。(1) An amino acid characterized in that one or more carbon atoms are labeled with ^1^3C. However, all carbon atoms are ^1
Excludes those in which ^3C is present and those in which only the carbon atom of the carboxyl group is ^1^3C.
とを特徴とする発酵法又は酵素法による請求項1記載の
アミノ酸の製造法。(2) The method for producing an amino acid according to claim 1 by a fermentation method or an enzymatic method, characterized in that a ^1^3C-labeled carbon source is used as the carbon source.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP03406790A JP3166160B2 (en) | 1989-02-15 | 1990-02-15 | New (1) and (3) C-labeled amino acids and their fermentative or enzymatic production |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1-35527 | 1989-02-15 | ||
JP3552789 | 1989-02-15 | ||
JP03406790A JP3166160B2 (en) | 1989-02-15 | 1990-02-15 | New (1) and (3) C-labeled amino acids and their fermentative or enzymatic production |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02291284A true JPH02291284A (en) | 1990-12-03 |
JP3166160B2 JP3166160B2 (en) | 2001-05-14 |
Family
ID=26372866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP03406790A Expired - Lifetime JP3166160B2 (en) | 1989-02-15 | 1990-02-15 | New (1) and (3) C-labeled amino acids and their fermentative or enzymatic production |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3166160B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002501006A (en) * | 1998-01-05 | 2002-01-15 | ナイコムド イメージング エーエス | Magnetic resonance survey method |
KR100332211B1 (en) * | 1994-12-09 | 2002-08-28 | 에스케이케미칼주식회사 | Process for prepararation of N-acetylglutamine as radiolabeled compound |
-
1990
- 1990-02-15 JP JP03406790A patent/JP3166160B2/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100332211B1 (en) * | 1994-12-09 | 2002-08-28 | 에스케이케미칼주식회사 | Process for prepararation of N-acetylglutamine as radiolabeled compound |
JP2002501006A (en) * | 1998-01-05 | 2002-01-15 | ナイコムド イメージング エーエス | Magnetic resonance survey method |
JP4764548B2 (en) * | 1998-01-05 | 2011-09-07 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | Magnetic resonance investigation method |
Also Published As
Publication number | Publication date |
---|---|
JP3166160B2 (en) | 2001-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2003122076A (en) | METHOD FOR ENZYMATIC PRODUCTION OF AMINO ACIDS AND DERIVATED AMINO ACIDS FROM THE PHOSPHOGLYCERATE FAMILY | |
JPH0523191A (en) | Production of d-pantothenic acid | |
JPH02186994A (en) | Production of l-amino acid by fermentation | |
JPH02291284A (en) | Novel 13c-labeled amino acid and its fermentative or its enzymatic preparation | |
CN107723317A (en) | A kind of method that itaconic acid is produced in Escherichia coli | |
JPS5922516B2 (en) | Method for producing L-phenylalanine | |
JP2670838B2 (en) | Method for producing L-α-amino acids | |
JPS63258588A (en) | Production of l-valine by fermentation | |
JPH0591895A (en) | Production of d-serine | |
JP3289349B2 (en) | Method for producing D-alanine by fermentation method | |
JPH01317394A (en) | Production of l-alpha-amino acid | |
JPS5816691A (en) | Preparation of l-lysine | |
JPS61177993A (en) | Production of l-isoleucine | |
JPH02207793A (en) | Production of d-beta-hydroxyamino acid | |
JPS6083593A (en) | Production of l-arginine by fermentation method | |
JPS6261593A (en) | Production of l-amino acid or nucleic acid by fermentation method | |
JPH074265B2 (en) | Method for producing D-alanine by fermentation method | |
JPS61260891A (en) | Production of l-threonine by fermentation method | |
JPH06181787A (en) | Production of l-alpha-aminoadipic acid | |
JPS63192395A (en) | Production of l-isoleucine | |
JPH01317393A (en) | Production of l-alpha-amino acid | |
JPH05276965A (en) | Production of dalanine by fermentation method | |
JPS58158191A (en) | Preparation of l-serine | |
JPH01112992A (en) | Production of l-isoleucine | |
JPS63269991A (en) | Production of l-isoleucine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EXPY | Cancellation because of completion of term |